ALK and non-small cell lung carcinoma: This real‐world retrospective observational study evaluating pembrolizumab as first‐line treatment for advanced NSCLC patients with a TPS ≥50% and without sensitizing EGFR mutations or ALK translocations, showed a PFS of 10.1 months (95% CI, 8.8 to not reached).